Introduction {#sec1-1}
============

Diabetic nephropathy (DN) is a disorder afflicting the kidneys, in the form of damage to the glomerular basement membrane, mesangial cell proliferation and glomerulosclerosis. DN is the third leading cause of death, among end-stage renal disease (ESRD) patients.\[[@ref1]\] It accounts for 25--40% of all cases with ESRD, after over 6--25 years and 0--8 years of manifestation of insulin-dependent diabetes mellitus (IDDM) and non insulin-dependent diabetes mellitus (NIDDM) respectively. Metabolic derangements are present in diabetes patients from the onset itself; which contributes to hyperglycemia. This in turn activates four major pathways\[[@ref2]\] of hyperglycemic damage such as nonenzymatic glycosalation, polyol pathway, hexose monophosphate shunt pathway and protein kinase C pathway mainly. Resulting in overproduction of superoxide that is a reactive oxygen species; thereby leading to oxidative stress and glomerular damage.

In Ayurveda, direct nomenclature of DN is not found. Regarding the manifestation of *Upadrava* (\~complications) in *Madhumeha* patients its stated as, the *Dushita Medas* (improperly formed fat tissue) along with *Kapha*, does *Dooshana* of *Kleda* and gets transformed to *Mootra* (\~urine). This cause obstruction at the *Mootravaha Srotas* and transforms *Madhumeha* into incurable form leading to manifestations of *Upadrava*.\[[@ref3]\]

Diabetic nephropathy presents with hyper filtrationfirst, followed by renal hypertrophy, microalbuminuria, and hypertension (HTN), later proteinuria and ESRD. Proteinuria on a long run manifests with pitting oedema as a resultant of hypoalbuminaemia. This symptom can be equated with *Kaphaja Shotha* explanation, which states "*Nipeeditho Na Cha Unnamati*" (swelling of pitting) nature.\[[@ref4]\] There are no references suggesting manifestation of *Shotha*, as an *Upadrava* of *Madhumeha*. It could be considered as the resultant of *Basti Marmabhighata*.\[[@ref5]\] Ayurveda has identified the organ system "*Basti*" as the *Moola* of *Mootravaha Srotas*, and it\'s an organ, which interpolates the whole of the urinary system. The involvement of *Mootravaha Srotas* in *Madhumeha Samprapti* exists from the very beginning of its pathogenesis. *Basti Marmabhighata* can be a sequel due to the *Ksharana* (passage) of *Uttarottara Dushya*\[[@ref6]\] in the urine.

There is no specific treatment available at present in contemporary science. The optimal therapy for this is prevention;\[[@ref7]\] as it necessitates dialysis, which is much cumbersome. Life style modification is an integral part in its management where a moderate protein diet, low sodium and low potassium diet is encouraged. Considering DN under *Yapya Vyadhi* is precise, where even a slight variation in the diet brings about increase in proteinurea, which is explained in classics with the lines *Pathyahara Viharairryapyo Yapaneeyaha*.\[[@ref8]\] The diseases involving *Marma* can be counteracted by careful intervention through use of *Rasayana* drugs.\[[@ref9]\] The use of *Rasayanas* such as *Shilajatu*, *Mandoora Bhasma*, *Guggulu*, *Triphala* are taken in the present work, keeping the above in mind.

Study objective {#sec2-1}
---------------

To evaluate the combined effect of (1) *Shilajitvadi Vataka*, (2) *Punarnavadi Mandura*, (3) *Triphala Guggulu*, (4) *Pippalimooladi Paneeya* added with *Amrita* and *Bringaraja* on *Madhumeha Janya Upadrava* with special reference to DN.

Materials and Methods {#sec1-2}
=====================

Design of study {#sec2-2}
---------------

This is a single-blind observational clinical study with pre- and post-test design.

Source of data and sampling methods {#sec2-3}
-----------------------------------

### Source of data {#sec3-1}

A total of 23 patients suffering from *Madhumeha Janya Upadrava* (DN) were selected randomly from outpatient department, inpatient department and also special camp conducted for the purpose of the institution. Subjects were enrolled in the study after taking their informed consent. Eight of these patients lost to follow-up, and the study was completed on 15 patients. The study was conducted after the ethical clearance obtained from the Institutional Ethics Committee.

### Reason for dropouts {#sec3-2}

In the present clinical study, 23 patients were registered out of which 8 dropouts were observed due to following reasons. One patient had scrotal swelling at the time of admission for the study, as his condition progressed to generalized edema it was discontinued. Another patient had peripheral neuropathy where the patient symptoms was not been able to monitor only with the above medications taken for the study, so to avoid bias it was not taken. Rest all patients failed to come for follow-up even after repeated phone contact. Probably as the patients were screened in earlier asymptomatic period; based on values of microalbuminuria, the meticulous awareness toward disease status was lacking, even after exhaustive clarification. As the patient was not sentient enough to understand the upshot of the disease.

Inclusion criteria {#sec2-4}
------------------

Known case of diabetic patients since 0--30 years, of either sex, aged between 20 and 80 years, who showed positive results for diabetic retinopathy changes were includedAsymptomatic/symptomatic diabetic patients who are afebrile, who have not done any vigorous exercise in previous 48 h, showing positive results for microalbuminuria (\>30 μg/24 h) with or without macroalbuminuria were selectedBoth fresh and treated cases were included.

Exclusion criteria {#sec2-5}
------------------

Patients having other complications of diabetes like cardiomyopathy were excludedPatients with recurrent urinary tract infections, marked HTN or obesity were excluded, as these conditions fallaciously rise microalbuminuriaPatients with hyperkalemia and other uremic symptoms are excludedPatients having other systemic disorders which interfere with the course of treatment are excluded.

Diagnostic criteria {#sec2-6}
-------------------

Fundoscopy - shows diabetic retinopathy changesLaboratory investigations - 24 h microalbuminuria with or without changes in serum albumin, serum creatinine, blood urea.

Investigations {#sec2-7}
--------------

### Special investigations {#sec3-3}

Ocular fundoscopyMicroalbuminurea - by 24 h urine protein analysisMacroalbuminuria - Urine for microscopic examinationSerum albuminSerum creatinineBlood urea nitrogen.

### Nonspecific investigation {#sec3-4}

Blood for hemoglobin percentage, total blood count, differential count, erythrocyte sedimentation rate, fasting blood sugar (FBS), postprandial blood sugar (PPBS)Urine routine investigations - Urine sugar, albumin and microscopic analysis.

Other investigations: If necessary, in concluding DN and excluding other forms of diabetic renal disease.

Interventions {#sec2-8}
-------------

*Shilajatvadi Vataka*\[[@ref10]\] - 1/2 *karsha* (6 g) twice a day empty stomach with 100 mL of milk, before food*Punarnavadi Mandoora*\[[@ref11]\] -- 2 g, 3 times a day after food*Pippali Mooladi Paneeya*\[[@ref12]\] - added along with *Amrita*\[[@ref13]\] and *Bringaraja*-approximately 30 mL, twice a day, before food*Triphala Guggulu*\[[@ref14]\] - 3 g, twice a day, after food along with *Pathya Aahara* and *Vihara*.

The dose of the medicines was altered considering the condition of the patient. Total duration of treatment was for 48 days. During the treatment period general condition assessment was done once in 15 days. Follow-up period was for 2 months.

Assessment and follow-up {#sec2-9}
------------------------

Response of the treatment was evaluated on the basis of score system from 0 to 3 (see criteria of assessment), where change of score indicates clinical improvement or deterioration. Effect on swelling was measured with measuring tape. The glomerular filtration rate (GFR) was measured using Cockcroft-Gault equation:
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Multiply by 0.85 for women.\[[@ref15]\]

All patients were assessed for general condition at 15 days interval until 48^th^ day of the treatment. Later follow-up for 2 months. GFR - Grading was done from 0 to 3.\[[@ref16]\] GFR is not a significant indicator of glomerular damage in early stages of DN. Microalbuminuria is a better indicator for progression and also to decide the prognosis of renal disease in earlier stages.\[[@ref17]\]

Efficacy and safety parameters {#sec2-10}
------------------------------

### Efficacy variable {#sec3-5}

The efficacy variables were subjective parameters like *Akshikoota shotha* (retro orbital oedema), *Pada Shotha* (pedal edema), *Dourbalyata* (fatigue), *Agnimandhya* (loss of appetite), and objective parameters like microalbuminuria, serum albumin, serum creatinine, GFR, blood urea and albuminuria (AL), blood pressure and FBS and PPBS.

### Safety variable {#sec3-6}

Any side-effects as experienced by the patient or observed by the investigator during the course of treatment with the study drug were recorded in case record form.

Criteria of assessment {#sec2-11}
----------------------

### Glomerular filtration rate {#sec3-7}

Criteria: ScoreSevere: \<15 mL/min/1.73 m^2^-3Moderate: \<30--90 mL/min/1.73 m^2^-2Mild: \>125 mL/min/1.73 m^2^-1Normal: 125 mL/min/1.73 m^2^-0.

### Albuminuria {#sec3-8}

Criteria: ScoreSevere: \<15 mL/min/1.73 m^2^-3Moderate: \<30--90 mL/min/1.73 m^2^-2Mild: \>125 mL/min/1.73 m^2^-1Normal: 125 mL/min/1.73 m^2^-0.

### Microalbuminuria (24 h) {#sec3-9}

Criteria: ScoreAbnormal: \>200 μg/min% - 3Moderate: 100--200 μg/min% - 2Mild: \>30--100 μg/min% - 1Normal: \<30 μg/min% - 0.

### Pada Shotha (Pedal oedema) {#sec3-10}

Criteria: ScoreSevere: 3Moderate: 2Mild: 1Normal: 0.

### Akshikoota Shotha (retro orbital oedema) {#sec3-11}

Criteria: ScoreSevere: 3Moderate: 2Mild: 1Normal: 0.

Statistical analysis {#sec2-12}
--------------------

Assessment of the patients was done before the treatment, after 15, 30 and 48^th^ day the treatment. The data were collected and analyzed, the total score of before treatment, during and after treatment was assessed using students paired *t*-test, descriptive statistics and contingency coefficient. Analysis was done through SPSS (Statistical Presentation System Software) for Windows, version 14.0, evaluation version (SPSS, 2005, SPSS Inc., New York, NY, USA).

Observations {#sec2-13}
------------

Most of the patients (66.7%) were of 60--80 years of age, followed by 20--40 years of age (20%) found prone to DN. Out of total 15 patients 9 (60%) were males and 6 (40%) were females. In study type 1 diabetic patients outnumbered type 2 diabetics (60% vs. 40%), maximum number of patients (10 i.e. 66.7%) showed familial inheritance of DM, 53.3% patients developed DN after 1--10 years duration of diabetes 86.7% had association of HTN along with DM. Maximum number of patients that is, 10 (66.7%) of them had mild nonproliferative diabetic retinopathy (NPDR), 4 (26.7%) had moderate NPDR. Presence of retinopathy changes was included only as a screening, so as to differentiate from other forms of diabetic renal disease; no post treatment retinopathy screening done.

Results {#sec1-3}
=======

Effect of therapy {#sec2-14}
-----------------

### Subjective parameters {#sec3-12}

There was symptomatic improvement in *Pada Shotha* (pedal edema) \[[Figure 1](#F1){ref-type="fig"}\], *Akshikoota Shotha* (retroorbital edema) \[[Figure 2](#F2){ref-type="fig"}\]. Urine volume and weight was within normal in most of the patients. These parameters showed no significant improvement statistically. The *Agni* status assessed as either *Manda*, *Madhyama* or *Teekshana*. Statistically highly significant improvement was observed in *Agni* status \[[Figure 3](#F3){ref-type="fig"}\].

![Improvement in *Pada Shotha* (\~pedal edema)](AYU-35-378-g002){#F1}

![Improvement in *Akshikoota Shotha*](AYU-35-378-g003){#F2}

![Improvement in *Agni* status](AYU-35-378-g004){#F3}

### Objective parameters {#sec3-13}

Significant improvement was observed in microalbuminuria. The difference of pre- and post-test mean of 83.76 μg/24 h. The mean increase in GFR in study subjects was about 2.3813, which showed statistically insignificant association \[[Table 1](#T1){ref-type="table"}\]. The mean serum albumin in the study subjects remained stable during the study period. Statistically, it showed insignificant improvement. Stable serum albumin levels may further indicates that there was no significant proteinuria in the study subjects. The mean difference of pre- and post-serum creatinine test was 0.1133, which showed statistically insignificant decrease \[[Table 1](#T1){ref-type="table"}\]. The improvement denotes prognosis only in late stages of DN, as serum creatinine is known to be late biomarker in DN. Statistically insignificant increase was seen in blood urea levels with a mean difference of −1.3000.

###### 

Effect therapy on biochemical parameters (*n*=15)
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The mean difference in FBS was 13.20 mg/dl which showed statistically insignificant association and in PPBS the mean difference was 19.33 mg/dl which showed statistically insignificant association \[[Table 1](#T1){ref-type="table"}\].

Systolic pressure decreased by 6 mmHg, diastolic pressure decreased by 3 mmHg, and mean arterial pressure decreased insignificantly \[[Table 2](#T2){ref-type="table"}\]. In AL overall improvement individually was good, but statistically insignificant improvement \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect therapy on blood pressure (*n*=15)

![](AYU-35-378-g006)

###### 

Effect of therapy on albuminuria
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Long term administration on the same medicaments had shown encouraging results. One patient was on dialysis since 6½ months. Had underwent 79 dialysis, had GFR 10.83 before treatment, which increased to 13.41 after 48 days of treatment and further rose to 25.60 mL/min/1.73 m^2^ with lowering of serum creatinine levels from 5.2 to 2.2 after 8 months of treatment. As it\'s the late biomarker in DN,\[[@ref18]\] the improvement in the creatinine levels shows the prognosis. Finally the patient was stopped from dialysis after observing the above improvement in GFR. Thus researches should be directed in this field to prove the effectiveness of the combination in DN patients, only then the generalization of effect in dialysis could be made.

Safety evaluation {#sec2-15}
-----------------

Most of patients showed inconvenience with ingestion of medication, in particular to odor of *Gomutra* (cow\'s urine) in *Punarnavadi Mandoora* and *Triphala Guggulu*. The patients were counseled for the same, thereby continued. Three patients complained of *Urodaha* (burning sensation in epigastrium) with *Pippalimooladi Paneeya*, such patients were advised to reduce to once daily dosage. If symptoms persisted then, during such symptomatic period the medications were discontinued for few days and was later restarted.

Discussion {#sec1-4}
==========

*Shilajatu* is a time tested drug and regularly used by Ayurvedic practitioners in renal disorders with assured effects. The active principle in *Shilajatu* is fulvic acid. Fulvic acid significantly increased superoxide dismutase activity.\[[@ref19]\] Experimental studies showed that fulvic acids diminished the development and progression of diabetes, and assisted in the treatment.\[[@ref19]\] *Shilajatu Punarnava*, *Guggulu*, *Mandoora*, *Triphala* are drugs said as *Naimittika Rasayanas* beneficial in *Prameha*, *Shotha*, and in renal disorders. Furthermore, the combination was found effective by experts in clinical practice and hence the above combination selected. Hence, *Naimithika Rasayanas* act as an adjuvant to the specific *Vyadhihara Chikitsa* prescribed for the disease and enhances their effect. These clear the *Srotas* (channels of circulation) by clearing the *Aparipakwa Medas* which is the main culprit formed as a result of *Dhatwagnimandhya*. The ingredients of *Pippalimooladi Paaneeya* have *Deepana* (stomachic), *Pachana* (digestive), *Shothahara* (reduces swelling), *Bastishodhaka* (clears renal pathway) and *Kaphahara* (removes the adherent dosas causing obstruction in renal vasculature) actions. Thus, it helps to remove the obstruction at glomerulus and also peripheral circulatory vessels. Thus by cleansing and activating the micro-circulatory channels, circulation and tissue perfusion will be increased thereby providing sufficient nutrition to the tissues.

Fundoscopy was included as a diagnostic criteria to confirm the renal disease is due to diabetes; as it\'s stated that - A diabetic can develop nondiabetic renal disease like anyone but the finding of diabetic retinopathy strongly suggests that any proteinuria is due to diabetic glomerulosclerosis.\[[@ref20]\] Thus in the study the prognostic assessment of the same was not done.

The outcome of treatment after 48 days showed statistically significant improvement in levels of microalbuminuria, highly significant in *Agni* improvement, and improvement in GFR by 2.3813 mL/min/1.73 m^2^ that was statistically nonsignificant. The drug combination has been shown encouraging results in a patient on dialysis with improvement of GFR from 10.83 to 25.60 mL/min/1.73 m^2^. This patient was stopped dialysis; thus administering medication for longer duration could be beneficial. Thus researches should be directed in this field to prove the effectiveness of this, in DN patients in later stages, only then the generalization of effect in dialysis could be made.

The drugs also found effective to stabilize the risk factors of DN like blood glucose levels, HTN as well. During the study period, the weight of patients and values of serum creatinine, serum albumin, blood glucose were stable without much variation, which shows that the drug combination is effective enough to monitor the risk factors of DN and prevent the disease from further progression.

Conclusion {#sec1-5}
==========

Microalbuminuria is the powerful screening tool for diagnosis and prognosis of DN in early stages. Statistically significant improvement in microalbuminuria has proved the effectiveness of the drugs used in the study in retarding the progression of glomerular injury. The work has shed a ray of hope in management strategy for DN. The beneficial effects of Rasayana drugs can be established thereby. Research efforts can be instituted in larger samples for further precision.
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